Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 201–300 of 1,000
Angiogenesis: A Target in Solid Tumors, Also in Leukemia?
Schmidt, T., & Carmeliet, P. (2011) · Hematology · doi:10.1182/asheducation-2011.1.1 · Cited by 92
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
Witzig, T. E., Nowakowski, G. S., Habermann, T. M., Goy, A. H., Hernandez‐Ilizaliturri, F. J., Chiappella, A., Vitolo, U., Fowler, N. H., & Czuczman, M. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv102 · Cited by 92
“Based on potential synergy between lenalidomide and dexamethasone in MCL cells [20] and established clinical studies in multiple myeloma [58, 59], lenalidomide 25 mg, d1-21/28 plus dexamethasone 40 mg weekly for ≤12 cycles was evaluated in relapsed/refractory MCL (n = 33) [50].”
BackgroundMutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Perumal, D., Imai, N., Laganà, A., Finnigan, J. P., Melnekoff, D. T., Leshchenko, V. V., Solovyov, A., Madduri, D., Chari, A., Cho, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2309 · Cited by 97
“Immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide have been ascribed to have immunostimulatory effects in multiple myeloma (9, 10).”
BackgroundWolschke, C., Stübig, T., Hegenbart, U., Schönland, S. O., Heinzelmann, M., Hildebrandt, Y., Ayuk, F. A., Atanackovic, D., Dreger, P., Zander, A. R., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.10.004 · Cited by 94
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 88
Ocio, E. M., Fernández-Lázaro, D., San-Segundo, L., López-Corral, L., Corchete, L. A., Gutiérrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., et al. (2015) · Leukemia · doi:10.1038/leu.2014.238 · Cited by 87
Self-citationThrombosis is associated with inferior survival in multiple myeloma
Kristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Schulman, S., & Landgren, O. (2012) · Haematologica · doi:10.3324/haematol.2012.064444 · Cited by 103
“However, during the same time period, venous thromboembolism (VTE) has been increasingly observed in patients with multiple myeloma, primarily those who were treated with thalidomide and lenalidomide, in combination with dexamethasone and/or combination chemotherapy.(6-8) Recently, we showed that the risk of VTE and a…”
BackgroundDimopoulos, M. A., & Terpos, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq370 · Cited by 121
Self-citationImmunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
Pal, R., Monaghan, S. A., Hassett, A. C., Mapara, M. Y., Schafer, P. H., Roodman, G. D., Ragni, M. V., Moscinski, L. C., List, A. F., & Lentzsch, S. (2009) · Blood · doi:10.1182/blood-2009-05-221077 · Cited by 91
“However, the use of IMiDs has been associated with 2 major adverse effects: (1) higher incidence of neutropenia that is the most common reason for holding or termination of treatment, and (2) increased risk for venous thromboembolism (VTE) that is further amplified with combination therapy.”
BackgroundVoorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07647.x · Cited by 88
“…lenalidomide and the proteasome inhibitor bortezomib, GCs remain an important component of multi-agent chemotherapy for newly-diagnosed and relapsed/refractory multiple myeloma (Jagannath et al, 2005; Rajkumar et al, 2005, 2008b; Harousseau et al, 2006; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundOcio, E. M., Maiso, P., Chen, X., Garayoa, M., Álvarez-Fernández, S., San‐Segundo, L., Vilanova, D., López‐Corral, L., Montero, J. C., Hernández‐Iglesias, T., et al. (2008) · Blood · doi:10.1182/blood-2008-09-177774 · Cited by 90
“10,11 Zalypsis (PM00104; N-[[(6aS,7R,13S,14S,16R)-5-(acetyloxy)6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocin-16yl]methyl]-3-[3-(trifluoromethyl)phenyl]-2E-propenamide) (Figure 1A) is a new synthetic alkaloid related to Jorumycin12 (a co…”
BackgroundSelf-citationDelforge, M., Minuk, L. A., Eisenmann, J.-C., Arnulf, B., Canepa, L., Fragasso, A., Leyvraz, S., Langer, C., Ezaydi, Y., Vogl, D. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.120121 · Cited by 90
“Although lenalidomide in combination with low-dose dexamethasone (Rd) is an established standard treatment option in patients with relapsed/refractory MM, recent data have emerged on the efficacy of this combination in patients with NDMM.(1,5,10,11,14-18) The randomized pivotal phase III FIRST trial (Frontline Investi…”
BackgroundSelf-citationRecent improvement in survival of patients with multiple myeloma: variation by ethnicity
Pulte, D. D., Redaniel, M. T., Brenner, H., Jansen, L., & Jeffreys, M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.827188 · Cited by 91
Landgren, O. (2013) · Hematology · doi:10.1182/asheducation-2013.1.478 · Cited by 87
Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
Zamagni, E., Brioli, A., Tacchetti, P., Zannetti, B. A., Pantani, L., & Cavo, M. (2011) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1273085 · Cited by 90
“Dimopoulos et al (2007)59 Relapsed/refractory Len-Dex vs Dex No 177 11 Randomized 176 5 Klein et al (2009)100 Relapsed/refractory Len-Dex LMWH 45 2 Retrospective Baz et al (2006)66 Relapsed/refractory Len-Doxo ASA 62 9 Phase 2 Richardson et al (2007)85 Relapsed/refractory Len-Vel No 27 0 Phase 1…”
BackgroundMechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond
Moudgil, R., & Yeh, E. T. H. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.027 · Cited by 100
Clinical pharmacokinetics and pharmacodynamics of lenalidomide
Chen, N., Zhou, S., & Palmisano, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0432-1 · Cited by 86
Management of older adults with multiple myeloma
Palumbo, A. P., & Mina, R. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.04.001 · Cited by 91
“[40] and [41] In a phase III trial, lenalidomide plus high-dose dexamethasone (RD) was compared with lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed MM patients, both eligible and ineligible for ASCT.”
BackgroundMethodLenalidomide in the treatment of multiple myeloma: a review
Armoiry, X., Aulagner, G., & Facon, T. T. F. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00920.x · Cited by 96
Self-citationLimaverde‐Sousa, G., Sternberg, C., & Ferreira, C. G. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.009 · Cited by 88
“Lenalidomide was FDA approved for patients with relapsed or refractory multiple myeloma, showing lower rates of constipation and neuropathy than thalidomide, but an increased myelosuppresion was observed [82].”
BackgroundDanhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12677 · Cited by 84
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
van de Donk, N. W. C. J., Kamps, S., Mutis, T., & Lokhorst, H. M. (2012) · Leukemia · doi:10.1038/leu.2011.214 · Cited by 81
Luisi, A. D., Ferrucci, A., Coluccia, A. M. L., Ria, R., Moschetta, M., de Luca, E., Pieroni, L., Maffia, M., Urbani, A., Pietro, G. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2381 · Cited by 84
“, NJ) is an oral immunomodulatory drug (IMiD) with demonstrated efficacy and tolerability in patients with multiple myeloma (MM) (1,2).”
BackgroundMitsiades, C. S., Davies, F. E., Laubach, J. P., Joshua, D., Miguel, J. S., Anderson, K. C., & Richardson, P. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0760 · Cited by 83
“glucocorticoids, compared with corresponding single agents or doublets.(2,3,6,7,82) Furthermore, high rates and depth of response have”
Self-citationNiesvizky, R., Martin, T. G., Bensinger, W. I., Alsina, M., Siegel, D. S., Kunkel, L. A., Wong, A. F., Lee, S., Orlowski, R. Z., & Wang, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3352 · Cited by 82
“relapsed or refractory multiple myeloma receiving RD in 2 phase III studies (23, 24), 1 patient receiving CRd in the current study experienced a grade 3 thromboembolic event.”
BackgroundBone marrow angiogenesis and progression in multiple myeloma.
Ria, R., Reale, A., Luisi, A. D., Ferrucci, A., Moschetta, M., & Vacca, A. (2011) · PubMed · Cited by 95
Patriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 84
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabo, Z., & Garderet, L. (2019) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 79
Vascular complications of selected cancer therapies
Daher, I. N., & Yeh, E. T. H. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1375 · Cited by 81
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study
Richardson, P. G., Chanan‐Khan, A. A., Alsina, M., Albitar, M., Berman, D., Messina, M., Mitsiades, C. S., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08265.x · Cited by 80
Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis
Niraula, S., Amir, E., Vera-Badillo, F., Šeruga, B., Ocaña, A., & Tannock, I. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8437 · Cited by 81
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
Laubach, J. P., Mahindra, A., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., Ghobrial, I. M., Carreau, N., Hideshima, T., Anderson, K. C., & Richardson, P. G. (2009) · Leukemia · doi:10.1038/leu.2009.179 · Cited by 78
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78
A review of the history, properties, and use of the immunomodulatory compound lenalidomide
Zeldis, J. B., Knight, R., Hussein, M., Chopra, R., & Muller, G. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05974.x · Cited by 77
Self-citationAvet-Loiseau, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.489 · Cited by 77
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
How I treat fragile myeloma patients
Larocca, A., & Palumbo, A. P. (2015) · Blood · doi:10.1182/blood-2015-05-612960 · Cited by 79
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
van de Donk, N. W. C. J., Lokhorst, H. M., Dimopoulos, M. A., Cavo, M., Morgan, G. J., Einsele, H., Kropff, M. H., Schey, S., Avet‐Loiseau, H., Ludwig, H., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.008 · Cited by 81
Self-citationApproach to chemotherapy-associated thrombosis
Oppelt, P., Betbadal, A., & Nayak, L. V. (2015) · Vascular Medicine · doi:10.1177/1358863x14568705 · Cited by 77
Lenalidomide: a novel anticancer drug with multiple modalities
Galustian, C., & Dalgleish, A. G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802627903 · Cited by 76
“Activity has been shown to increase markedly when lenalidomide is combined with dexamethasone: two randomised Phase III trials in North America and Europe [5,6] have demonstrated that the combination regimen provides greater efficacy than with dexamethasone alone, with combined response rates of 59 versus 21 – 24% for…”
BackgroundCurrent approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 82
Chanan-Khan, A. A., Niesvizky, R., Hohl, R. J., Zimmerman, T. M., Christiansen, N. P., Schiller, G. J., Callander, N. S., LISTER, J. W., Oken, M. M., & Jagannath, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902748971 · Cited by 75
“In fact, the dexamethasone group in our study reflects patients with more advanced stage of disease when compared with dexamethasone group in recently reported studies [19,20] in relapsed/ refractory myeloma with a median time to progression of 108 days vs.”
ResultMohty, B., Cheikh, J. E., Yakoub‐Agha, I., Avet‐Loiseau, H., Moreau, P., & Mohty, M. (2011) · Leukemia · doi:10.1038/leu.2011.310 · Cited by 80
Booth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01423 · Cited by 78
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
Dimopoulos, M. A., Miguel, J. F. S., & Anderson, K. C. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01542.x · Cited by 79
“Although low rates of grade ‡3 peripheral neuropathy were observed (<2% of patients), venous thromboembolic events were reported in approximately 10–15% of patients receiving lenalidomide plus dexamethasone (8, 9).”
BackgroundSelf-citationChen, C. I., Reece, D. E., Siegel, D. S. D., Niesvizky, R., Boccia, R. V., Stadtmauer, E. A., Abonour, R., Richardson, P. G. G., Matous, J., Kumar, S. K., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07728.x · Cited by 76
“…safety profile) in the treatment of patients with relapsed or refractory MM (Corral et al, 1999; Hideshima et al, 2000; Richardson et al, 2002, 2006; Dimopoulos et al, 2007; Weber et al, 2007), and transfusion-dependent International Prognostic Scoring System (IPSS)-defined Low- and Int-1-risk…”
InfluentialSelf-citationDurable remission with salvage second autotransplants in patients with multiple myeloma
Shah, N., Ahmed, F., Bashir, Q., Qureshi, S., Dinh, Y. T., Rondón, G., Wen, S., Thall, P. F., Khan, H. M., Giralt, S., et al. (2011) · Cancer · doi:10.1002/cncr.26662 · Cited by 78
Dumontet, C., Hulin, C., Dimopoulos, M. A., Belch, A. R., Dispenzieri, A. A., Ludwig, H., Rodon, P., Droogenbroeck, J. V., Qiu, L., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0133-x · Cited by 77
Self-citationOrlowski, R. Z., Moreau, P., Niesvizky, R., Ludwig, H., Oriol, A., Chng, W. J., Goldschmidt, H., Yang, Z., Kimball, A. S., & Dimopoulos, M. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.018 · Cited by 74
Self-citationIslam, M. B., Lustberg, M. B., Staff, N. P., Kolb, N., Alberti, P., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12334 · Cited by 80
“tially no grade 3 or 4 events in comparison with placebo or other drugs, especially thalidomide.(108,109) In any case, there are no publi-”
BackgroundTherapy‐related peripheral neuropathy in multiple myeloma patients
Morawska, M., Grzasko, N., Kostyra, M., Wojciechowicz, J., & Hus, M. (2015) · Hematological Oncology · doi:10.1002/hon.2149 · Cited by 71
Thrombosis and Hemostatic Abnormalities in Hematological Malignancies
Colombo, R., Gallipoli, P., & Castelli, R. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.05.003 · Cited by 73
Venous thromboembolism in the hematologic malignancies
Falanga, A., Marchetti, M., & Russo, L. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283592331 · Cited by 73
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Lemieux‐Blanchard, É., Hulin, C., Caillot, D., Tardy, S., Dorvaux, V., Michel, J., Gastinne, T., Rossi, C., Legouge, C., Touzeau, C., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.11.013 · Cited by 72
“In a pivotal trial for the approval of bortezomib as monotherapy in patients with relapsed and refractory MM, the median PFS was 7 months [4], whereas in pivotal trials for the approval of lenalidomide in combination with dexamethasone in the same group of patients, the median time to progression was approximately 11…”
BackgroundBerdeja, J. G., Jagannath, S., Zonder, J. A., Badros, A. Z., Kaufman, J. L., Manges, R., Gupta, M., Tendolkar, A. V., Lynch, M. J., Bleickardt, E. W., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.007 · Cited by 70
The role of natural killer cells in immunity against multiple myeloma
Godfrey, J. K., & Benson, D. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.676175 · Cited by 79
Management of treatment-related adverse events in patients with multiple myeloma
Mateos, M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70009-8 · Cited by 70
Zaja, F. F., Luca, S. D., Vitolo, U., Orsucci, L., Levis, A., Salvi, F., Rusconi, C., Ravelli, E., Tucci, A., Bottelli, C., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.051813 · Cited by 70
“Dexamethasone was included in the study in an attempt to achieve synergistic clinical effects based on in vitro observations(11) as well as positive clinical results observed in combination with lenalidomide in multiple myeloma.(12,13) However, in vitro studies in lymphoma cells have recently demonstrated that lenalid…”
BackgroundResultThalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 75
Kamalaporn, P., Saravanan, R., Cirocco, M., May, G. R., Kortan, P. P., Kandel, G. P., & Marcon, N. E. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832c9346 · Cited by 69
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A., Lonial, S., & Richardson, P. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67
“Lenalidomide plus dexamethasone was compared with highdose dexamethasone in two randomized, placebo-controlled studies in RR MM: the MM-009 and MM-010 trials [31,32].”
BackgroundMethodDimopoulos, M. A., Christoulas, D., Ρούσσου, Μ., Kastritis, E., Migkou, M., Gavriatopoulou, M., Matsouka, C., Mparmparoussi, D., Psimenou, E., Grapsa, I., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01432.x · Cited by 69
Self-citationMechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Yang, W., & Lin, S.-F. (2015) · BioMed Research International · doi:10.1155/2015/341430 · Cited by 84
“Treatment strategies for MM patients include two-drug regimens such as bortezomibdexamethasone [62], lenalidomide-dexamethasone [15, 16, 86, 94], or thalidomide-dexamethasone [63, 84, 92, 93] and three-drug regimens such as bortezomib-thalidomidedexamethasone [63–66], bortezomib-melphalan-prednisone [68, 69], or lenal…”
BackgroundThe role of the proteasome in AML
Csizmar, C. M., Kim, D.-H., & Sachs, Z. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.112 · Cited by 68
How I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Self-citationImmunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Rosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 70
Self-citationSecond auto-SCT for treatment of relapsed multiple myeloma
Gonsalves, W. I., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Hogan, W. J., & Kumar, S. K. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.183 · Cited by 67
Antiangiogenesis in haematological malignancies
Li, W. W., Hutnik, M., & Gehr, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07372.x · Cited by 67
“…multiple myeloma demonstrated an improved response rate (59Æ2% vs. 22Æ5%; P < 0Æ001) and increased median TTP (48Æ1 vs. 20Æ1 weeks; P < 0Æ001) for patients treated with lenalidomide and dexamethasone, compared with dexamethasone alone (Wang et al, 2006; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundLenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis
Zagouri, F., Kastritis, E., Gavriatopoulou, M., Sergentanis, T. Ν., Ψαλτοπούλου, Θ., Terpos, E., & Dimopoulos, M. A. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.869329 · Cited by 66
Self-citationBiological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
Martiniani, R., Di Loreto, V., Di Sano, C., Lombardo, A., & Liberati, A. M. (2012) · Advances in Hematology · doi:10.1155/2012/842945 · Cited by 63
“a significant benefit in overall survival (38 versus 31,6 months, P < 0, 045) for those patients initially randomized to be treated with lenalidomide-dexamethasone combination [8, 26].”
BackgroundElotuzumab for the treatment of multiple myeloma
Wang, Y., Sanchez, L. J., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0284-z · Cited by 66
Swan, D., Rocci, A., Bradbury, C. A., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15684 · Cited by 68
Teh, B. W., Harrison, S. J., Worth, L. J., Thursky, K., & Slavin, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.025 · Cited by 71
Pegourié, B., Karlin, L., Benboubker, L., Orsini‐Piocelle, F., Tiab, M., Auger‐Quittet, S., Rodon, P., Royer, B., Leleu, X. P., Bareau, B., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25459 · Cited by 67
“were asymptomatic for VTE at inclusion, and requiring melphalan-thalidomide-prednisone (patients in first line),(15) or lenalidomide-dexamethasone (patients in relapse).(7) All patients were over 18 years of age, with an Eastern cooperative Oncology Group performance status of 0 to 2.”
BackgroundMethodGoldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 70
“In part this was related to better outcome of Rd in the control arm with median PFS of 18.8 months compared to the expected 11 months based on published data at the time of trial conception (CC-5013-MM-009 [17] and CC-5013-MM-010 [18] trials).”
InfluentialHuang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62
“The treatment schedules for LD [18], TD [19], and MVP [20], as well as the related dosage adjustment [1] were described previously.”
MethodOffidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 61
“44,45 In contrast, the rate of severe neutropenia with BVD in our study appears lower than that reported with Rd (18 vs 36%).”
InfluentialJakubowiak, A. J., Richardson, P. G., Zimmerman, T., Alsina, M., Kaufman, J. L., Kandarpa, M., Kraftson, S., Ross, C. W., Harvey, C., Hideshima, T., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09173.x · Cited by 62
“…into our study, more comparable to the patient population enrolled into MM-009 and MM-010 studies, indicated a PR or better rate of 70%, and PFS was 27·7 months, which appears improved when compared to historical data with lenalidomide–dexamethasone (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundResultInfluentialQian, Z., Zhang, L., Cai, Z., Sun, L., Wang, H., Yi, Q., & Wang, M. L. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.09.027 · Cited by 63
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq178 · Cited by 76
Self-citationBuda, G., Ricci, D., Huang, C. C., Favis, R., Cohen, N., Zhuang, S. H., Harousseau, J.-L., Sonneveld, P., Bladé, J., & Orlowski, R. Z. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0992-3 · Cited by 61
“One example is that of the immunomodulatory agent lenalidomide which, when combined with dexamethasone, is superior to corticosteroids alone [5, 6].”
BackgroundSelf-citationMicallef, I. N. M., Ho, A. D., Klein, L. M., Marulkar, S., Gandhi, P. J., & McSweeney, P. A. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.118 · Cited by 61
“4 Lenalidomide is a less toxic analog of thalidomide that, when used in combination with dexamethasone, has been shown to be superior in efficacy to dexamethasone alone in patients with relapsed and refractory MM”
Solimando, A. G., Vià, M. D., Cicco, S., Leone, P., Lernia, G. D., Giannico, D., Desantis, V., Frassanito, M. A., Morizio, A., Tascon, J. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070997 · Cited by 62
“Bortezomib in combination with dexamethasone (bortezomib-dexamethasone—VD) [157] or the triple-therapy with also liposomal doxorubicin (bortezomib, doxorubicin and dexamethasone—PAD) [157] and lenalidomide-dexamethasone (lenalidomide-dexamethasone—RD) schedule [67,158,159] have showed significant prolongation of PFS i…”
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 63
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
Borsi, E., Terragna, C., Brioli, A., Tacchetti, P., Martello, M., & Cavo, M. (2014) · Translational research · doi:10.1016/j.trsl.2014.12.001 · Cited by 67
Musallam, K. M., Dahdaleh, F. S., Shamseddine, A. I., & Taher, A. T. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.09.008 · Cited by 63
“As with thalidomide, lenalidomide containing regimens for treatment of MM have been shown to be associated with an increased risk of VTE [28,61–65] (Table 5).”
BackgroundRychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 60
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 62
Madan, S., Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Buadi, F., Hayman, S. R., Detweiler-Short, K., Dingli, D., Zeldenrust, S., Lust, J., et al. (2011) · Blood · doi:10.1182/blood-2011-04-350009 · Cited by 60
Klein, U., Neben, K., Hielscher, T., Heiß, C., Ho, A. D., & Goldschmidt, H. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1080-4 · Cited by 61
“Treatment consisted of lenalidomide (25 mg on days 1 to 21) and dexamethasone (cycle duration 28 days) according to the two phase III studies, which led to the approval of lenalidomide in relapsed and refractory MM patients [18, 19].”
Botta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 67
Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 58
Rodon, P., Hulin, C., Daley, L., Dauriac, C., Hacini, M., Decaux, O., Eisemann, J.-C., Fitoussi, O., Lioure, B., Voillat, L., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0140 · Cited by 61
“5% in the non US to 15% in the US trial (27, 28); patients had received much more rEPO in the US study, while no difference was found in terms of IMiDs-based therapeutic association (29).”
BackgroundSelf-citationKlein, U., Jauch, A. S., Hielscher, T., Hillengaß, J., Raab, M. S., Seckinger, A., Hose, D., Ho, A. D., Goldschmidt, H., & Neben, K. (2010) · Cancer · doi:10.1002/cncr.25775 · Cited by 61
Kröger, N. M., Shimoni, A., Schilling, G., Schwerdtfeger, R., Bornhäuser, M., Nagler, A., Zander, A. R., Heinzelmann, M., Brand, R., Gahrton, G., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07984.x · Cited by 60
Brioli, A., Klaus, M., Sayer, H. G., Scholl, S., Ernst, T., Hilgendorf, I., Scherag, A., Yomade, O., Schilling, K., Hochhaus, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03621-1 · Cited by 65
Miguel, J. F. S., Dimopoulos, M. A., Stadtmauer, E. A., Rajkumar, S. V., Siegel, D. S. D., Bravo, M. L. C., Olesnyckyj, M., Knight, R., Zeldis, J. B., Harousseau, J., et al. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.120 · Cited by 62
Self-citationEmerging therapies for multiple myeloma
Podar, K., Tai, Y., Hideshima, T., Vallet, S., Richardson, P. G. G., & Anderson, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802676278 · Cited by 62
“However, in patients receiving Len/Dex, neutropenia and thromboembolic events (DVT and pulmonary emboli) occurred in 41 and 30% and 15 and 11%, cases respectively [26,27] .”
BackgroundOncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3366 · Cited by 60
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.